Dr. Erik B. Lindblad Professional profile (truncated C.V.)
Erik B. Lindblad graduated from University of Copenhagen, Faculty of Natural Sciences in Biology. He specialized in Immunology at Statens Seruminstitut in Copenhagen in dr. J.V. Spärck’s Dept. of Immunology and at Institute of Forensic Medicine under dr. sc. Hanna E. Hansen, preparing and characterizing murine monoclonal antibodies against components of the human Major Histocompatibity Complex (HLA).
Dr. Lindblad’s Ph.D. project on vegetable lipid adjuvants for potential use in vaccines was carried out at Statens Seruminstitut, Vaccine Dept. under the supervision and guidance of dr.med. Iver Heron and professor, dr.med. Gunnar Bendixen, Rigshospitalet in Copenhagen.
Dr. Lindblad became responsible for developing the vaccine adjuvant business of Superfos Biosector, later known as Brenntag Biosector and he was the driving force in the upstart of the newly established vaccine adjuvant plant in Frederikssund in 1990/1991. He served here as General Manager and later as Technical Director and from 2014 – 2021 as Director of R&D at CRODA Denmark.
In the period 1993-2003 dr. Lindblad served as a member of the Editorial Board of the research journal VACCINE and he has authored a number of research papers, patent applications, reviews and book contributions.
Dr. Lindblad has served as co-supervisor/opponent for Ph.D. projects at University of Copenhagen, University of Ulm (Germany) and University of Kwazulu Natal (South Africa) and he has served as a guest teacher at WHO training courses at University of Lausanne, Switzerland. and as scientific advisory board member at various international meetings on vaccines and adjuvants.
Dr. Lindblad originally established his company, Inari ApS, in 2003 in connection to becoming a shareholder and supervisory board member of the Danish company STEMCARE who established cryopreservation facilities and biobanking for stem cells from human umbilical cord blood.
Dr. Lindblad is now an independent scientific consultant, and since 2023 serves in addition as a member of an expert group on aluminum safety aspects in parenteral nutrition solutions under the EU commission body (EDQM), and since 2024 as a member of the Advisory Board for Biologicals under the Danish Medicines Agency.